Published in Environ Health Perspect on August 01, 1998
Mercury toxicity and treatment: a review of the literature. J Environ Public Health (2011) 1.49
Plasma and urine dimercaptopropanesulfonate concentrations after dermal application of transdermal DMPS (TD-DMPS). J Med Toxicol (2013) 1.15
Environmental determinants of chronic disease and medical approaches: recognition, avoidance, supportive therapy, and detoxification. J Environ Public Health (2012) 1.08
Mercury intoxication resulting from school barometers in three unrelated adolescents. Eur J Pediatr (2004) 0.88
Commentary on "Transdermal DMPS". J Med Toxicol (2013) 0.75
Successful Splenectomy for Hypersplenism in Wilson's Disease: A Single Center Experience from China. PLoS One (2015) 0.75
Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res (1985) 3.44
Mercury released from dental "silver" fillings provokes an increase in mercury- and antibiotic-resistant bacteria in oral and intestinal floras of primates. Antimicrob Agents Chemother (1993) 2.40
Human studies do not support the methylation threshold hypothesis for the toxicity of inorganic arsenic. Environ Res (1993) 2.03
A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol (1995) 2.01
Chronic arsenic poisoning in the north of Mexico. Hum Toxicol (1983) 1.88
DMSA and DMPS--water soluble antidotes for heavy metal poisoning. Annu Rev Pharmacol Toxicol (1983) 1.76
Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu Rev Pharmacol Toxicol (1997) 1.68
Role of thiols in the in-vitro methylation of inorganic arsenic by rat liver cytosol. Biochem Pharmacol (1988) 1.55
Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc Natl Acad Sci U S A (1989) 1.49
Arsenic methylation patterns before and after changing from high to lower concentrations of arsenic in drinking water. Environ Health Perspect (1996) 1.48
Study of inorganic arsenic methylation by rat liver in vitro: relevance for the interpretation of observations in man. Arch Toxicol (1985) 1.43
meso-2,3-Dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu Rev Pharmacol Toxicol (1990) 1.35
Chronic arsenic toxicity from drinking tubewell water in rural West Bengal. Bull World Health Organ (1988) 1.33
Enzymatic methylation of arsenic compounds: assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Chem Res Toxicol (1995) 1.26
Identification of a novel, thiol-containing co-factor essential for glutathione reductase enzyme activity in trypanosomatids. Mol Biochem Parasitol (1985) 1.13
Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology (1995) 1.09
Comparative in vitro methylation of trivalent and pentavalent arsenicals. Toxicol Appl Pharmacol (1995) 1.09
Mono- and dimethylation of arsenic in rat liver cytosol in vitro. Chem Biol Interact (1996) 1.05
Enzymatic methylation of arsenic compounds. III. The marmoset and tamarin, but not the rhesus, monkeys are deficient in methyltransferases that methylate inorganic arsenic. Toxicol Appl Pharmacol (1996) 1.02
Urinary mercury after administration of 2,3-dimercaptopropane-1-sulfonic acid: correlation with dental amalgam score. FASEB J (1992) 1.01
Mobilized mercury in subjects with varying exposure to elemental mercury vapour. Int Arch Occup Environ Health (1991) 1.00
Determination and metabolism of dithiol chelating agents. XVI: Pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration to human volunteers. J Pharmacol Exp Ther (1994) 0.98
Determination and metabolism of dithiol chelating agents. XII. Metabolism and pharmacokinetics of sodium 2,3-dimercaptopropane-1-sulfonate in humans. J Pharmacol Exp Ther (1991) 0.97
Urinary excretion of meso-2,3-dimercaptosuccinic acid in human subjects. Clin Pharmacol Ther (1989) 0.97
Relation between airborne arsenic trioxide and urinary excretion of inorganic arsenic and its methylated metabolites. Br J Ind Med (1992) 0.97
Lack of methylation of inorganic arsenic in the chimpanzee. Toxicol Appl Pharmacol (1995) 0.96
Potential health hazard of use of mercury in dentistry: critical review of the literature. Environ Res (1987) 0.95
Reduction and binding of arsenate in marmoset monkeys. Arch Toxicol (1985) 0.92
Treatment of mercury and lead poisonings with dimercaptosuccinic acid and sodium dimercaptopropanesulfonate. A review. Analyst (1995) 0.91
Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans: II. Urinary mercury, porphyrins and neurobehavioral changes of dental workers in Monterrey, Mexico. J Pharmacol Exp Ther (1995) 0.91
Fluorometric determination of 2,3-dimercaptopropane-1-sulfonic acid and other dithiols by precolumn derivatization with bromobimane and column liquid chromatography. J Chromatogr (1986) 0.88
Determination and metabolism of dithiol chelating agents. VIII. Metal complexes of meso-dimercaptosuccinic acid. Toxicol Appl Pharmacol (1989) 0.87
Determination and metabolism of dithiol chelating agents. VII. Biliary excretion of dithiols and their interactions with cadmium and metallothionein. Fundam Appl Toxicol (1990) 0.85
Enzymatic methylation of arsenic compounds: IV. In vitro and in vivo deficiency of the methylation of arsenite and monomethylarsonic acid in the guinea pig. Mutat Res (1997) 0.83
Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans. III. Urinary mercury after exposure to mercurous chloride. J Pharmacol Exp Ther (1996) 0.83
Determination and metabolism of dithiol-chelating agents: electrolytic and chemical reduction of oxidized dithiols in urine. Anal Biochem (1987) 0.82
[Pharmacology of a new antidote unithiol]. Farmakol Toksikol (1958) 0.81
Determination and metabolism of dithiol chelating agents. VI. Isolation and identification of the mixed disulfides of meso-2,3-dimercaptosuccinic acid with L-cysteine in human urine. Toxicol Appl Pharmacol (1989) 0.81
Childhood lead poisoning and its treatment. Annu Rev Pharmacol Toxicol (1993) 0.79
Evaluation of the safety issue of mercury release from dental fillings. FASEB J (1993) 0.77
[Mercury mobility through DMPS (Dimaval) in persons with and without amalgam fillings]. Zahnarztl Mitt (1989) 0.77
Determination and metabolism of dithiol chelating agents. IV. Urinary excretion of meso-2,3-dimercaptosuccinic acid and mercaptosuccinic acid in rabbits given meso-2,3-dimercaptosuccinic acid. Biochem Pharmacol (1989) 0.77
Interactions of the chelating agent 2,3-dimercaptopropane-1-sulfonate with red blood cells in vitro. I. Evidence for carrier mediated transport. Chem Biol Interact (1982) 0.77